To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00207168|
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : April 22, 2011
|Condition or disease||Intervention/treatment||Phase|
|AIDS||Behavioral: Compliance||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||120 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Multi-center, Open Label Study in Well Controlled Treatment-experienced HIV- Infected Patients to Assess Compliance With a Once-daily Regimen|
|Study Start Date :||April 2004|
|Actual Primary Completion Date :||December 2006|
|Actual Study Completion Date :||December 2006|
- To determine over 24 weeks the levels of adherence in two groups of HIV-infected subjects randomized to receive either a once daily 3-drug regimen or to continue a minimum 3-drug regimen requiring more frequent dosing.
- To demonstrate that once daily therapy is not-inferioir to continued multiple dosing in terms of proportion of patients with treatment failure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00207168
|Study Director:||Bristol-Myers Squibb||Bristol-Myers Squibb|